Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies

Gallego, G; Bridges, JFP; Flynn, T; Blauvelt, BM; Niessen, LW

Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies

Gallego, G

Bridges, JFP Flynn, T Blauvelt, BM Niessen, LW

Permalink

Publication Type:: Journal Article
Citation:: International Journal of Technology Assessment in Health Care, 2012, 28 (3), pp. 339 - 346
Issue Date:: 2012-07-01

Closed Access

	Filename	Description	Size
	2011004743OK.pdf		260.6 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Gallego, G https://orcid.org/0000-0002-3243-8176	en_US
dc.contributor.author	Bridges, JFP	en_US
dc.contributor.author	Flynn, T	en_US
dc.contributor.author	Blauvelt, BM	en_US
dc.contributor.author	Niessen, LW	en_US
dc.date.issued	2012-07-01	en_US
dc.identifier.citation	International Journal of Technology Assessment in Health Care, 2012, 28 (3), pp. 339 - 346	en_US
dc.identifier.issn	0266-4623	en_US
dc.identifier.uri	http://hdl.handle.net/10453/22431
dc.description.abstract	Objectives: There is a growing need for efficient procedures for identification of emerging technologies by horizon scanning systems. We demonstrate the value of best-worst scaling (BWS) in exploring clinicians- views on emerging technologies that will impact outcomes in hepatocellular carcinoma (HCC) in the next 5 to 10 years. Methods: Clinicians in Asia, Europe, and the United States were surveyed and their views about eleven emerging technologies relevant to HCC were explored using BWS (case 1). This involved systematically presenting respondents with subsets of five technologies and asking them to identify those that will have the most and least impact on HCC within 5 to 10 years. Statistical analysis was based on sequential best-worst and analyzed using conditional logistic regression. Results: A total of 120 clinicians uniformly distributed across ten countries completed the survey (37 percent response rate). Respondents were predominately hepatologist (41 percent) who focused on HCC (65 percent) and had national influence in this field (39 percent). Respondents viewed molecular targeted therapy (p <.001) and early detection of HCC (p <.001) as having most potential, while improved surgical techniques (p <.001) and biopsy free HCC diagnostics (p <.001) were viewed upon negatively. Conclusions: We demonstrate that BWS could be an important research tool to facilitate horizon scanning and HTA more broadly. Our research demonstrates the value of including clinicians- preferences as a source of data in horizon scanning, but such methods could be used to incorporate the opinions of a broad array of stakeholders, including those in advocacy and public policy. © Copyright 2012 Cambridge University Press.	en_US
dc.relation.ispartof	International Journal of Technology Assessment in Health Care	en_US
dc.relation.isbasedon	10.1017/S026646231200027X	en_US
dc.subject.classification	Health Policy & Services	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Carcinoma, Hepatocellular	en_US
dc.subject.mesh	Liver Neoplasms	en_US
dc.subject.mesh	Data Collection	en_US
dc.subject.mesh	Biomedical Technology	en_US
dc.subject.mesh	Health Personnel	en_US
dc.subject.mesh	Technology Assessment, Biomedical	en_US
dc.subject.mesh	United States	en_US
dc.subject.mesh	Asia	en_US
dc.subject.mesh	Europe	en_US
dc.title	Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	28	en_US
utslib.for	1402 Applied Economics	en_US
utslib.for	1117 Public Health and Health Services	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Strength - CENSOC - Study of Choice
utslib.copyright.status	closed_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	28	en_US

Abstract:

Objectives: There is a growing need for efficient procedures for identification of emerging technologies by horizon scanning systems. We demonstrate the value of best-worst scaling (BWS) in exploring clinicians- views on emerging technologies that will impact outcomes in hepatocellular carcinoma (HCC) in the next 5 to 10 years. Methods: Clinicians in Asia, Europe, and the United States were surveyed and their views about eleven emerging technologies relevant to HCC were explored using BWS (case 1). This involved systematically presenting respondents with subsets of five technologies and asking them to identify those that will have the most and least impact on HCC within 5 to 10 years. Statistical analysis was based on sequential best-worst and analyzed using conditional logistic regression. Results: A total of 120 clinicians uniformly distributed across ten countries completed the survey (37 percent response rate). Respondents were predominately hepatologist (41 percent) who focused on HCC (65 percent) and had national influence in this field (39 percent). Respondents viewed molecular targeted therapy (p <.001) and early detection of HCC (p <.001) as having most potential, while improved surgical techniques (p <.001) and biopsy free HCC diagnostics (p <.001) were viewed upon negatively. Conclusions: We demonstrate that BWS could be an important research tool to facilitate horizon scanning and HTA more broadly. Our research demonstrates the value of including clinicians- preferences as a source of data in horizon scanning, but such methods could be used to incorporate the opinions of a broad array of stakeholders, including those in advocacy and public policy. © Copyright 2012 Cambridge University Press.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/22431